CONFERENCE DAY ONE

8:00 am Check-In & Morning Coffee

8:50 am Chair’s Opening Remarks

• Christopher Phelps Senior Vice President & Head of Early Drug Discovery, Nurix Therapeutics

Advancing Screening Technologies to Access Diverse Chemical Matter & Accelerate the Discovery of Stabilizing & Modulating Induced Proximity Therapies for Novel Targets

9:00 am Identifying MYC Interactome Modulators via Small Molecule Microarray Screening

• Charles Y. Lin Senior Vice President - Research & Development, Kronos Bio

9:30 am Non-Degrading Macrocyclic Type I Molecular Glues: Glue Libraries for Inhibiting PPI’s

• Rick Ewing Vp, Rapafusyn Pharmaceuticals

10:00 am Utilization of Mass Spectrometry to Efficiently Identify & Validate DUB Recruiters & DUBTACs

• Tyzoon Nomanbhoy Vice President, Chemical Biology, Vicinitas Therapeutics

10:30 am Morning Break & Speed Networking

Pioneering Platforms to Define the Framework for Rationally Designing Safe & Efficient Induced Proximity Drugs with Novel Mechanisms of Action

11:30 am Discovery of FKBP Molecular Glues Using DEL & Diverse Protein Domains

• Trevor Zandi Postdoctoral Scientist, Novartis Biomedical Research

12:00 pm Round Table: Tackling the Rationale Design of Molecular Glues with Advancing Platforms to Generate High Efficacy Clinical Candidates

• Kathleen Seyb Senior Vice President - Biology & Translational Sciences, TRIANA Biomedicines

12:30 pm Magnet Biomedicine’s TrueGlue Platform: The Next Frontier in Precision Localization

• Matthew Hayward Vice President - Drug Discovery, Magnet Biomedicine

1:00 pm Networking Lunch Break

Understanding Chemistry & Biology Fundamentals to Inform & De-Risk Novel Emerging Induced Proximity Approaches in New Disease Paradigms

2:00 pm Discovery Proteomics for Investigating Interactomes

• Andrew Zhang Director, Chemical Biology, AstraZeneca

2:30 pm Round Table: Deliberating the Biological Synergy of Un-Endogenous Protein Partners when Co-opted as Targets for Induced Proximity to Mitigate Off Target Toxicity

• Kelly Rainbolt Senior Scientist - Biochemical & Cellular Engineering, Lyterian Therapeutics

3:00 pm Afternoon Networking Break

4:00 pm Improving the Potency of Nature’s Molecular Glues by Leveraging Synthetic Biology to Drug Protein-Protein Interfaces

• Edmund Graziani Chief Executive Officer & Co-Founder, Apertor Pharmaceuticals

4:30 pm Progressing Induced Proximity Approaches to Specifically Mediate Chromatin Regulation & Expand the Repertoire of Clinically Relevant Disease Targets

• Jun Qi Assistant Professor – Medicine, Dana-Farber Cancer Institute

5:00 pm Chairs Closing Remarks & End of Conference Day One